Editor’s note: This article is written with respect for the realities pharmacy owners are navigating. The intention is to provide perspective on what the latest funding variation may mean in practical terms.

Pharmacy funding has once again entered a period of adjustment. Variation 7 introduces an overall funding uplift of approximately 3 percent across the sector 

At face value, this signals some recognition of the cost pressures community pharmacies have been operating under. However, a sector-wide percentage uplift does not automatically translate into improved sustainability at the level of an individual pharmacy. The distinction matters.
‍

A funding uplift does not equal a profitability uplift

The uplift has been applied across several dispensing and service-related components, including handling, per-pack, and case mix service lines. At the same time, APAS funding has been reduced and redistributed into these service line fees, changing the structure of revenue for many pharmacies.

The modelling suggests total service revenue across the sector may increase by around 3 percent. Whilst headline figure signals engagement with sector cost pressures, it is important to be clear. A 3 percent funding uplift is unlikely to restore margins or materially strengthen profitability for most pharmacies.

Over recent years, operating costs have risen well beyond that level. Wage inflation, workforce shortages, increased reliance on locums, higher rent, rising insurance premiums, compliance requirements, and escalating IT costs have all added sustained pressure. For many pharmacies, cost growth in key categories has exceeded 3 percent per annum for multiple consecutive years.

In that context, the uplift may slow the rate at which margins have been tightening. It does not reverse the structural cost pressure most pharmacies are carrying. This is simply economic reality.

APAS redistribution will affect pharmacies differently

The redistribution of APAS funding into dispensing-related service signals a gradual move toward aligning funding more directly with dispensing and service activity, rather than maintaining a separate pooled mechanism.

Pharmacies serving higher proportions of Māori and Pacific patients for example, and other priority populations have therefore experienced different funding profiles under that framework. As funding is reallocated into activity-based components, the financial impact will vary depending on historical APAS reliance, and patient demographics.

For some, the redistribution may feel neutral. For others, it may reduce predictability or create revenue pressure where demographic weighting previously provided support. Headline averages therefore conceal individual realities.

Immunisation adjustments require careful interpretation

Variation 7 also adjusts immunisation administration fees. General immunisations have received a noticeable percentage increase, with an increase in immunisation administration fees for influenza and COVID-19 by 4.02% an 11.65% increase in the immunisation administration fees for all other vaccines.

The introduction of a co-administration fee adds further nuance. Under previous arrangements, influenza and COVID-19 vaccinations generated separate administration payments. Under the co-administration model, when both are delivered together, the combined fee structure differs from the historical total of two standalone payments.

For pharmacies with high seasonal vaccination throughput, this distinction is financially relevant. Although the percentage increase for general immunisations appears strong in isolation, influenza and COVID-19 vaccinations represent the majority of activity for many pharmacies. When co-administered, the overall revenue outcome will be lower than under prior separate payment arrangements. As a result, the aggregate financial benefit of immunisation adjustments is unlikely to be as significant as headline percentages suggest.

Clarity before reaction

In times of funding change, it is understandable to focus on headline percentage movements. The more important question for any individual pharmacy is how those changes interact with its own structure.

A sector-wide uplift does not automatically improve net profitability. In most cases, it will not fully offset sustained operating cost growth that has accumulated over recent years.

What determines sustainability is the true margin profile of the business, the resilience of its cost base, the stability of its staffing model, the sensitivity to demographic weighting, and the composition of service lines.

Without clarity at this level, funding changes can feel insufficient or destabilising. With clarity, they can be interpreted proportionately and planned for.

A steady approach in a shifting environment

Funding environments will continue to evolve. For pharmacy owners, steadiness comes from understanding structure rather than reacting to headlines. When there is space to interpret funding movements in practical terms, decision-making becomes calmer and more intentional.

In periods of change, taking time to understand what the funding shifts mean for your own business can prevent reactive decisions. Clarity does not remove pressure, but it does make the next steps easier to see. When the funding model shifts, clarity becomes a strategic asset.

‍